CTS Ltd

TRIUMPHARMA was founded in 2002 , is a full service CRO that supports the pharmaceutical and the biotech industries in introducing new solutions to the pharmaceutical markets, with core strength in :
Clinical Trials [Phase I - Phase IV] including Clinical Data Management and BE/BA studies.

Over the years we have successfully conducted more than 300+ US-FDA submissions , EU/ANSAM/Bfarm/MHRA submissions (NDAs & ANDAs) and MENA/JFDA submissions, using HVs and patients in various therapeutic areas such as CV diseases, Gastro-intestinal disorders, Respiratory/Pulmonary disorders, Metabolic disorders, Endocrinology, Nephrology/Hepatology, Rheumatoid Arthritis Disorders of immune systems, Neurology/Psychiatry, Gynecology, Acute/Chronic infections and Oncology.

TRIUMPHARMA has experience in many of the POC indications, in addition to our experience in early phase studies such as Asthma, NASH, Parkinson, AF, Diabetes, and others. We have also conducted many studies on monoclonal antibodies including HAE and biosimilar /biotech products.

TRIUMPHARMA encompass a total bed capacity of 80 beds across our two floors ((over 200 beds with our hospital sites) and 5 LC/MS/MS machines. We have a dedicated facility and team for Phase I-IV clinical trials conducted in compliance with ICH GCP guidelines. And we have our own diagnostic and screening medical lab, Bioanalytical lab with state of the arts LC/MS/MS equipment’s, the trained PIs, Research Nurses, CRCs, CRAs, Project Management, certified and trained Spirometer technicians, dedicated Data Entry team with familiarity with the relevant and most updated clinical software’s used in trials, Qualified site and IMPs Depot .We are also able to offer our clients the benefit of a large collective experience when formulating and implementing regulatory strategies and study designs.

We have successfully been inspected by US-FDA , EMA, French Ministry of Health-ANSM, German Ministry of Health- Bfarm, Turkish MOH, GCC, UAE MOH, JFDA,

TCG Lifesciences Pvt. Limited (formerly "Chembiotek Research International"​) is a leading global Contract Researchand Manufacturing Services (CRAMS) company in the area of drug discovery and development. We started our operations in 2001 in Kolkata, India and currently have our presence in the United States, Europe, and Japan.
We have a strong talent pool of 800+ qualified and trained scientists (including 150+ PhDs), drawn from the best domestic and international institutes and industry. Our services span chemistry, in vitro and in vivo pharmacology, analytical development and validation, and specialty chemicals. We offer specific/functional solutions to integrated projects across multiple therapeutic areas with specific focus on Inflammation & Pain, Infectious Diseases, Central Nervous System and Oncology. Our research infrastructure includes world-class chemistry and biology laboratories, animal facility, electrophysiology laboratory, BSL 2 laboratory, and cGMP facilities at our R&D centers.
Our Offerings:
DISCOVERY SERVICES
Functional Chemistry
• Scaffolds & Building Blocks
• Library Synthesis
• Parallel Synthesis
• Medicinal Chemistry Singletons
• Solid Phase and Solution Phase Peptide Synthesis
Functional Biology
• In vitro Pharmacology
• ADME
• Pharmacokinetics and Pharmacodynamics (PK/PD)
• In vitro Toxicology
• In vivo Pharmacology
Fully Integrated Services
• Medicinal Chemistry Design
• Lead Generation
• Lead Optimization
• Preclinical Candidate Selection

DEVELOPMENT SERVICES
• Rapid Scale-Up and cGMP Kilo Labs
• Route Evaluation
• Hazard Assessment & Reaction Calorimetry
• Process R&D
• Clinical Trial Materials Preparation
Analytical Services
• cGMP Analytical Lab
• Methods Development & Validation
• Forced Degradation Studies
• Impurity Profile Determination
• Impurity Isolation and Characterization
• Preparative Chromatography (chiral, SFC, and HPLC)
• Reference Standards Management
• ICH Stability Studies
MANUFACTURING SERVICES:

WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 4,100 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that "every drug can be made and every disease can be treated."

Established in Hyderabad, India in 1978, Gland Pharma is one of the fastest-growing small-molecule generic injectables-focused company, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets in the rest of the world. Gland Pharma has seven manufacturing facilities in India, comprising four facilities for finished formulations and three API facilities. We are focused on meeting diverse injectables needs with a stable supply of affordable and high-quality products. We have established a portfolio of injectables products across various therapeutic segments and delivery systems and are present in sterile injectables, oncology and ophthalmics with a focus on complex injectables.

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing and marketing companies in the world. It has been growing at about 25.5% CAGR over the last 5 years and crossed the $1.9 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 69% of its revenue coming from global business.

Currently ranked 9th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology and Oncology in India. It is also known for its range of products in other hospital-based therapeutic segments in the EU and US.

Intas operates 15 formulation, R&D and distribution facilities, of which 10 are in India, and the rest in the UK and Mexico. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars and NDDS products.

Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “biosimilars for billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies.

The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP certified manufacturing facility complemented with a GLP compliant QC lab.

Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces of our excellence.